We use cookies to deliver our online services. Details of the cookies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you agree to our use of cookies. To close this message click close.

Hogan Lovells Expands Corporate and Government Regulatory Practices With Addition of Life Sciences General Counsel John E. Osborn

10 January 2014

WASHINGTON, D.C. 10 January 2014 – Hogan Lovells today announced that John E. Osborn has joined its Corporate and Government Regulatory practices as a Senior Advisor, where he will focus on Life Sciences and Healthcare industry matters.

For more than twenty years, Osborn worked as a senior executive and general counsel with leading life sciences and healthcare companies.  He served as Executive Vice President & General Counsel with two Fortune 1000 firms:  Cephalon, Inc. during its period of extraordinary growth from a pre-commercial development stage firm to a multi-billion dollar international biopharmaceutical company, and US Oncology, Inc. where he worked to structure and negotiate a $2 billion sale of the company to McKesson.  While at Cephalon from 1997 to 2008, Osborn led negotiations on acquisitions and other complex commercial transactions, brought and settled intellectual property litigation that ensured continuing protection for a billion-dollar franchise product, resolved government investigations regarding product marketing and manufacturing quality issues, and led an effort to enact the Controlled Substances Export Reform Act of 2005.  In addition to managing all legal, corporate governance and intellectual property matters, Osborn also has been responsible for a wide range of business and policy functions, including government affairs and public policy, corporate communications, investor relations, risk management, internal audit, compliance, and quality assurance.  He joined the industry in 1992 as chief European counsel with a Merck joint venture company, and also has worked with west coast biotechnology companies Onyx Pharmaceuticals and Dendreon.

“John’s extensive experience with some of the most notable companies in the life sciences industry is an ideal complement to Hogan Lovells’ industry-focused approach that we bring to the practice of law,” said Asher Rubin, global co-head of Hogan Lovells’ Life Sciences Industry Sector Team. “We believe that John’s practical approach to helping companies achieve critical business objectives, within a complex legal and regulatory framework, will provide unique benefits for our life sciences clients.”

Osborn has been a visiting fellow in socio-legal studies at the University of Oxford, where he developed a comparative perspective on the regulation of off-label scientific and medical information. His article on the subject was published in 2010 in the Yale Journal of Health Policy, Law & Ethics and cited in 2012 by the majority in United States v. Caronia (2nd Circuit) in connection with its ruling that a misbranding conviction for alleged off-label promotion based upon truthful information was unconstitutional.

In 2008, Osborn was confirmed by the Senate as a member of the bipartisan United States Advisory Commission on Public Diplomacy.  From 1989 to 1992 he served with the U.S. Department of State during the George H.W. Bush administration. Earlier in his career, Osborn worked on Capitol Hill and was a law clerk to Judge Albert V. Bryan, Sr. of the U.S. Court of Appeals for the Fourth Circuit. He has been elected to membership in the Council on Foreign Relations and the American Law Institute.

Osborn holds a faculty appointment at the University of Washington, Seattle where he is an Affiliate Professor of Law and an Affiliate Lecturer of International Studies. He earned a J.D. from the University of Virginia School of Law, a M.I.P.P. from The Johns Hopkins University School of Advanced International Studies, and a B.A. in Economics and History from the University of Iowa.

Loading data